|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||122.88 - 124.23|
|52 Week Range||96.99 - 134.55|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||0.96 (0.78%)|
|1y Target Est||130.21|
The largest Insider Buys this week were for Celgene Corp. (CELG), Yum Brands Inc. (YUM), Omega Healthcare Investors Inc. (OHI) and Zimmer Biomet Holdings Inc. (ZBH). Director Ernest Mario bought 2,000 shares of CELG stock on Feb. 12 at the average price of $89.99. Warning! GuruFocus has detected 3 Warning Signs with CELG.
NuVasive share rose 11 percent to $54.85 at 9:57 a.m. in New York, after a report Friday in the Financial Times on the possible interest from the U.K. company. Smith & Nephew recently signaled its readiness to pursue a bigger deal, with Chief Executive Officer Namal Nawana saying last week the company wants to play in more areas of medical devices. The market questioned the rationale of buying NuVasive, however.
The largest Insider Buys this week were for AT&T Inc. (NYSE:T), Biogen Inc. (BIIB), Abbott Laboratories (ABT) and Zimmer Biomet Holdings Inc. (ZBH). Warning! GuruFocus has detected 5 Warning Signs with T. Click here to check it out. AT&T Inc. an American multinational telecommunications conglomerate that is the second largest provider of mobile telephone services and the largest provider of fixed telephone services in the U.S. It also provides broadband subscription television services through DirecTV.
When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation. The exact terms of any talks could not be learned, and the discussions may still fall apart, the FT reported. The acquisition would mark the first major move by Smith & Nephew Chief Executive Namal Nawana.
President and CEO of Zimmer Biomet Holdings Inc (NYSE:ZBH) Bryan C Hanson bought 2,100 shares of ZBH on 02/07/2019 at an average price of $119.02 a share.
Zimmer Biomet Holdings Inc NYSE:ZBHView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ZBH totaled $15.64 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Br, Feb. 06, 2019 -- In new independent research reports released early this.
Zimmer (ZBH) delivered earnings and revenue surprises of 0.00% and 0.54%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Warsaw, Indiana-based company said it had a loss of $4.42. Earnings, adjusted for asset impairment costs and non-recurring costs, were $2.18 per share. The results met Wall Street ...
- Net sales of $2.071 billion for the fourth quarter represent an increase of 0.1% over the prior year period, and an increase of 1.6% on a constant currency basis - Diluted loss per share for the fourth ...
The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.
WARSAW, Ind. , Jan. 29, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the 8 th Annual SVB Leerink Global Healthcare ...
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WARSAW, Ind., Jan. 25, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced U.S. Food and Drug Administration 510(k) clearance of the ROSA® Knee System for robotically-assisted total knee replacement surgeries. ROSA Knee features 3D pre-operative planning tools and real-time, intraoperative data on soft-tissue and bone anatomy designed to improve bone cut accuracy and range of motion gap analysis to potentially improve flexion and restoration of natural joint movement. "Complementing the skill and expertise of the surgeon with ROSA Knee's robotically-assisted technologies can improve accuracy, precision and consistency, which can improve patient satisfaction, clinical outcomes and efficiency," said Christopher J. Cannova, M.D., Washington Joint Institute at OrthoBethesda.
Medical device companies need to focus on value and disease prevention or their products risk becoming commodities, according to a recent report by consulting firm KPMG. Warning! GuruFocus has detected 3 Warning Signs with ZBH.